Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes

Loretta Fala. Am Health Drug Benefits. 2015 Mar.

. 2015 Mar;8(Spec Feature):70-4.

No abstract available

References

1. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. 2014. www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed August 25, 2014.
1. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010; 8:29. - PMC - PubMed
1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36:1033–1046. Erratum in: Diabetes Care. 2013; 36:1797. - PMC - PubMed
1. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013; 36(suppl 1): S11–S66. - PMC - PubMed
1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract. 2013; 19(suppl 2): 1–48. - PMC - PubMed